Gary Esq - GB Sciences Securities Sec
| GBLX Stock | USD 0.01 0 84.37% |
Insider
Gary Esq is Securities Sec of GB Sciences
| Phone | 866 721 0297 |
| Web | https://www.gbsciences.com |
GB Sciences Management Efficiency
The company has return on total asset (ROA) of (0.2082) % which means that it has lost $0.2082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (50.9796) %, meaning that it created substantial loss on money invested by shareholders. GB Sciences' management efficiency ratios could be used to measure how well GB Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Simon Beaudoin | Defence Therapeutics | 39 | |
| Sigal Arad | Enlivex Therapeutics | N/A | |
| Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
| Carrie Cesarone | Defence Therapeutics | 58 | |
| Sebastien Plouffe | Defence Therapeutics | 51 | |
| Moutih Rafei | Defence Therapeutics | 41 | |
| Oren Hershkovitz | Enlivex Therapeutics | 47 | |
| Shachar CPA | Enlivex Therapeutics | 47 | |
| Pr MD | Enlivex Therapeutics | 68 | |
Management Performance
| Return On Equity | -50.98 | |||
| Return On Asset | -0.21 |
GB Sciences Leadership Team
Elected by the shareholders, the GB Sciences' board of directors comprises two types of representatives: GB Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GBLX. The board's role is to monitor GB Sciences' management team and ensure that shareholders' interests are well served. GB Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GB Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Krin Kuethe, VP Cultivation | ||
| John Poss, President, CFO and COO | ||
| Gary Esq, Securities Sec | ||
| Zach Swarts, Chief CFO | ||
| MBA MBA, Chief Board |
GBLX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GB Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -50.98 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 10.19 M | |||
| Shares Outstanding | 379.21 M | |||
| Shares Owned By Insiders | 13.08 % | |||
| Price To Earning | 4.04 X | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 1.91 X | |||
| Gross Profit | (881.46 K) | |||
| EBITDA | 398.73 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GBLX Pink Sheet Analysis
When running GB Sciences' price analysis, check to measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.